H. (1970) . Toxicol. Appl. Pharmacol. 17, 337-343. Dibutylaminoethanol (Bu,AE) produces convulsions in rats leading to respiratory arrest regardless of route of administration. The lethality of 5 x LD50 doses of BuzAE can be readily overcome by artificial respiration for 2-4 hr. In vivo phrenic nerve-diaphragm preparations indicate that the respiratory arrest is due to a neuromuscular blockade. Spontaneous activity of the phrenic nerve increases during convulsions and persists during blockade. Pretreatment with mephenesin or diphenylhydantoin, but not pentobarbital, was effective in counteracting convulsions and respiratory arrest. BuzAE has also been shown to be a moderate inhibitor of acetylcholinesterase. It is proposed that the increased nerve activity during convulsions with its simultaneous increase in acetylcholine release, acts in concert with the moderate level of cholinesterase inhibition, producing a neuromuscular blockade due to excessive acetylcholine accumulation at the junction.
Dibutylaminoethanol (Bu,AE) has found use as a conditioning agent for cellulose acetate filaments to facilitate textile manufacture, a catalyst in polyurethane foam manufacture, an anticorrosion additive for lubricants and hydraulic fluids, in the manufacture of emulsifying and dispersing agents, and in the curing of silicone resins.
Bu,AE has been investigated by us because it is one of the more toxic in a long series of alkyl-substituted aminoethanols. The oral LD50 of this compound has been reported as 1.07 g/kg by Smyth et al. (1954) . Cornish et al. (1969) found that Bu2AE in drinking water at 0.2 and 0.4 g/kg per day in rats resulted in reduced body weight and slight increases in kidney weight without accompanying pathology. Inhalation studies at 70 ppm for 6 hr daily for 5 days, resulted in weight losses, chromodacryorrhea, tremors, and some convulsions. At that dose level there was 20 % mortality.
Characteristically Bu,AE acts by inducing strong clonic-tonic convulsions which closely resemble a Grand Ma1 seizure. These convulsions were noted after oral and intraperitoneal administrations as well as inhalation of Bu,AE. All observed mortalities due to Bu,AE were preceded by convulsions. Because of this close relationship, they were studied in greater detail.
METHODS
There appeared to be no qualitative difference in the convulsions associated with acute or subchronic exposures or with variations in route of administration. Like most alkyl-substituted aminoethanols, BuzAE is normally quite alkaline with a pK, of9.67 (Gero, 1963) . Prior to use, commercial Bu,AE(Eastman Organic Chemicals) was further purified by fractional vacuum distillation. It was then neutralized with HCI to avoid the direct effects of alkalinity. Doses are reported in terms of Bu,AE base. Statistical analyses of the ED50 and LD50 data were done using the logistic analysis of Berkson (1944), which we have programmed for computer use. Electroencephalograms were taken under pentobarbital anesthesia between right frontal and right parietal areas with the electrodes directly attached to the skull. In viva nerve-diaphragm preparations were prepared as illustrated in Fig. 1 . Mathematical analysis of nerve activity was done by computer-assisted polynomial regression. 
RESULTS
After ip injection the median effective dose for the production of convulsions was 50.6 mg/kg (95 % fiducial limits: 31.6-80.9), and the LD50 was found to be 89.1 mg/kg (95 % fiducial limits: 40.6-195.6). There is a significant overlap between convulsive dose and lethal dose. Many of the rats which reached the convulsive stage also died.
Shortly after Bu,AE injection, there appears to be an increase in rhythmic electrical activity of the EEG which becomes very pronounced during the ensuing convulsions (Fig. 2) . In this case, these convulsions were reduced to very heavy tremors under the influence of the barbiturate anesthesia. During light pentobarbital anesthesia, the rat will frequently wake up after Bu,AE and shortly go into frank convulsions. The convulsions then lead to a respiratory arrest and a flattening of the EEG due to anoxia. The convulsions arose centrally as indicated by the EEG and substantiated by the fact that convulsions disappeared distally upon spinal section.
The immediate cause of death after Bu,AE appears to be the respiratory arrest which follows immediately after the convulsions. We attempted to counteract the respiratory arrest phase by artificial respiration after doses up to 500 mg/kg ip Bu,AE. This represents approximately 5-6 LD50. The rats were placed under light pentobarbital anesthesia and respired via a tracheal cannula using a Physiograph respirator. After an initial period of moderate convulsions and tremors, the experimental animals stopped breathing spontaneously, as tested by briefly interrupting the artificial respiration. The animals did not develop cyanosis at any time during this treatment. The artificial respiration counteracted the respiratory failure, but not the convulsions.
After the convulsive phase, the animals appeared to be in a generalized state of flaccid paralysis for 2-4 hr. After these 2-4 hr of artificial respiration, all animals were able to resume breathing on their own and were able to walk a short time after that. When function was regained, the signs of tremors and convulsions did not reappear.
FIG. 2. EEG-right frontal to right parietal; electrodes placed on the surface of the skull in a rat after 250 mg/kg ip BQAE.
Since artificial respiration was effective in counteracting the lethality of Bu,AE due to respiratory arrest without appreciably affecting the convulsions, we investigated the nature of that respiratory arrest. For this investigation, we utilized the in uivo nervediaphragm preparation as illustrated in Fig. 1 . We were thus able to measure the spontaneous activity of the intact phrenic nerve, and also were able to study the effect of stimulating the phrenic nerve on the contractility of the rat diaphragm. Stimulating the phrenic nerve indicated that a neuromuscular blockade developed whose onset was dose related (Fig. 3) . For individual rats within these groups, the onset of the blockade was typically abrupt. There also was a general indication that the severity of the blockade was dose related.
The recordings of spontaneously occurring nerve activity exhibited a great deal more variability. The basic method of measurement, using a scaler and counting all impulses above a certain threshold voltage, plainly suffered from lack of sophistication and equipment. Nevertheless, the data in Fig. 4 demonstrate that some activity in the intact phrenic nerve persists even during the neuromuscular blockade, and that there is a trend toward higher nerve activity for higher dose levels of Bu,AE. Much of that increase occurs during the convulsive stage and is probably due to the increased central stimulation after Bu,AE. Many of the preceding data of course had to be gathered during artificial respiration. Without artificial respiration or other treatment, the time course of these events is normally quite short. At 250 mg/kg, which represents approximately a 3 x LD50 dose, time to first convulsion was typically 2.9 & 0.3 (mean f SE) min and time to death 7.8 i 1 .O min. Under these conditions, the mortality was 100 % in 10 experiments. The same dose was used in most of the subsequent experiments which tested various Bu,AE drug interrelations. We had previously demonstrated that Bu,AE was a moderately active inhibitor of acetylcholinesterase (Hartung and Cornish, 1968) . Therefore, we investigated the effect of pretreatment with atropine on Bu,AE-induced convulsions. The Bu,AE was injected when atropinization had been achieved, as judged by pupil size. Dosages of atropine ranging from 0.02 to 0.2 mg/kg had no significant effect on the time course or the outcome of convulsions and respiratory arrest induced by Bu,AE doses as low as 125 mg/kg. Since atropine is mainly effective in counteracting the parasympathomimetic effects of anticholinesterases, but not neuromuscular effects, these results were not unexpected.
The possibility still remained that this was a curarelike neuromuscular blockade. Therefore we employed 0.85 mg/kg iv edrophonium, which is a valuable antagonist against some curariform neuromuscular blockers. It too had no effect on the time course or outcome.
Since none of the tested peripherally acting antagonists to neuromuscular blocking agents had been effective in counteracting Bu2AE toxicity, we decided to test some of the centrally acting anticonvulsants.
Throughout our work with anesthetized rats we had noted that barbiturates in moderate doses were unable to control Bu*AE-induced convulsions. Therefore we investigated a series of other anticonvulsants.
Magnesium sulfate (1 mg/kg iv) given as pretreatment resulted in 1 survival in 6. The significance of that effect may be questionable. Higher dose levels may be more effective.
Mephenesin was far more effective as an anticonvulsant against Bu,AE (Table 1) . In these tests, a curious effect became evident. Animals which did not develop convulsions, survived without developing any indication of respiratory arrest. When the onset of convulsions could be delayed to 6 min, the rats usually survived. In those cases the convulsions were much weaker and alternated with heavy tremors for as long as 1.5 hr without producing a respiratory arrest.
Diphenylhydantoin (5 mg/kg iv) was the most effective drug for preventing Bu,AEinduced convulsions (Table 2) . It almost completely prevented convulsions and mortalities after normally lethal doses of Bu*AE.
On the other hand, trimethadione was ineffective in controlling Bu,AE-induced convulsions even at doses (150 mg/kg ip) which had been found effective in counteracting a lethal dose of the convulsant pentylenetetrazol. DISCUSSION Bu*AE has been shown to produce convulsions and neuromuscular blockade resulting in respiratory arrest. None of the peripherially acting drugs selected for possible antagonistic action to the neuromuscular blockade produced by Bu,AE had any noticeable effect. However, two centrally acting anticonvulsants were effective in counteracting both the convulsive seizures and the respiratory arrest produced by Bu,AE. Thus for BuzAE there appears to be a relationship between the primary mechanism causing convulsions and the subsequent neuromuscular blockade which results in death due to respiratory arrest.
Bu,AE appears to possess a duality in its mode of action. First, it produces a greatly increased CNS activity which results in strong tonic-clonic convulsions. Respiratory arrest due to the neuromuscular blockade develops during this period of elevated CNS activity. Since Bu,AE is also a moderate acetylcholinesterase inhibitor, this increased nerve activity with its simultaneous increase in release of acetylcholine at the junction, may result in a neuromuscular blockade due to excess acetylcholine at that site.
